Targazyme, Inc. is a clinical stage biopharmaceutical company developing breakthrough “point-of-care” products. These products improve clinical effectiveness, cost of care outcomes and safety in cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, regenerative medicine, and gene therapy.
The company’s proprietary ex vivo enzymatic glyco-engineering platform, fucosylation, improves the therapeutic effectiveness of cells. This platform directs the fucosylated cells to the sites of disease and inflammation. By doing this, higher retention leads to a superior therapeutic benefit.
Targazyme’s technology is broadly applicable to a range of therapeutic cells (natural or genetically-engineered). Targazyme’s product development strategy focuses on applying our technology to both established cell therapies, such as hematopoietic stem cell transplantation, and emerging therapies, such as cancer cell-based immunotherapies.